New hATTR Treatments Under Review for their ‘Value for Money’
Two vitally important reviews are underway for patisiran and inotersen, new treatments that have been trialed for hATTR patients. One review is led by the National Institute for Health and Clinical Excellence (NICE) in the UK. (more…)
ARC CEO Named Representative of Patient Engagement Collaborative
To strengthen patient involvement, the U.S. Food and Drug Administration (FDA) and the Clinical Trials Transformation Initiative (CTTI) announced the launch of the Patient Engagement Collaborative (PEC). (more…)
ARC Provides Vital Feedback for Evaluation of New hATTR Treatments
The Institute of Clinical and Economic Review (ICER), is an independent organization that seeks to improve healthcare value by providing comprehensive clinical and cost-effectiveness analyses of treatments. (more…)
ARC Launches Version Two of Powerful Amyloidosis Diagnostic App
A recent ARC survey showed that patients typically see four or more physicians before getting accurately diagnosed, and often those who were misdiagnosed were receiving treatment for their misdiagnosis. The Clinical Resources App was developed to provide healthcare professionals with...
Join our email list to stay up to date on the latest Amyloidosis news.
In this ARC Talks Webinar, Dr. Morie Gertz gave a 101 overview of clinical trials, including consideration in how they are designed, and the phases needed for drug development. Dr. Gertz also discussed current clinical trials that are evaluating the next generation of drugs for the treatment of AL and ATTR amyloidosis.
Original Presentation Date:
May 25, 2023
Key Webinar Highlights:
0:00 — Introduction
3:10 — Start of Dr. Gertz’s presentation
4:30 — The Necessity of Clinical Trials
13:50 — The Phases of Clinical Trials
23:23 — Definition of An Open Label Extension
24:47 — The Study of Vyndaquel for ATTR-CM Patients
26:18 — The Study of Drug Therapies for ATTR-PN/hATTR patients